Golden Throat Holdings Group Company Limited (6896.HK)
HKD 3.08
(-0.65%)
HKD 3.08
(-0.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 348.22 Million CNY | -1.46% |
| 2022 | 353.37 Million CNY | 1.06% |
| 2021 | 349.67 Million CNY | 19.76% |
| 2020 | 291.98 Million CNY | -23.4% |
| 2019 | 381.17 Million CNY | 2.59% |
| 2018 | 371.56 Million CNY | 9.06% |
| 2017 | 340.69 Million CNY | -9.34% |
| 2016 | 375.77 Million CNY | 17.65% |
| 2015 | 319.4 Million CNY | 22.35% |
| 2014 | 261.05 Million CNY | -4.08% |
| 2013 | 272.17 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 138.84 Million CNY | -34.55% |
| 2023 FY | 348.22 Million CNY | -1.46% |
| 2023 Q2 | 212.13 Million CNY | 6.56% |
| 2022 Q4 | 199.06 Million CNY | 29.0% |
| 2022 FY | 353.37 Million CNY | 1.06% |
| 2022 Q2 | 154.31 Million CNY | -7.15% |
| 2021 Q4 | 166.2 Million CNY | -9.41% |
| 2021 Q2 | 183.46 Million CNY | 13.92% |
| 2021 FY | 349.67 Million CNY | 19.76% |
| 2020 Q2 | 130.93 Million CNY | -26.96% |
| 2020 FY | 291.98 Million CNY | -23.4% |
| 2020 Q4 | 161.05 Million CNY | 23.0% |
| 2019 FY | 381.17 Million CNY | 2.59% |
| 2019 Q4 | 179.26 Million CNY | -11.22% |
| 2019 Q2 | 201.91 Million CNY | 0.53% |
| 2018 Q4 | 200.84 Million CNY | 17.64% |
| 2018 FY | 371.56 Million CNY | 9.06% |
| 2018 Q2 | 170.72 Million CNY | -14.66% |
| 2017 Q4 | 200.04 Million CNY | 42.23% |
| 2017 FY | 340.69 Million CNY | -9.34% |
| 2017 Q2 | 140.65 Million CNY | -41.42% |
| 2016 Q4 | 240.09 Million CNY | 76.95% |
| 2016 Q2 | 135.68 Million CNY | -26.62% |
| 2016 FY | 375.77 Million CNY | 17.65% |
| 2015 Q4 | 184.89 Million CNY | 37.45% |
| 2015 Q2 | 134.51 Million CNY | 2.21% |
| 2015 FY | 319.4 Million CNY | 22.35% |
| 2014 Q2 | 129.45 Million CNY | 102.03% |
| 2014 Q4 | 131.6 Million CNY | 1.66% |
| 2014 FY | 261.05 Million CNY | -4.08% |
| 2013 Q4 | 64.07 Million CNY | 0.0% |
| 2013 FY | 272.17 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -1325.749% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 90.98% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -880.17% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | 1.613% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -1936.165% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 41.078% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 71.665% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 30.834% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -60.747% |
| SSY Group Limited | 1.98 Billion HKD | 82.419% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -112.493% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -21.185% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 98.814% |